0000000000917738

AUTHOR

Simona Buccheri

showing 21 related works from this author

Cross-talk between gamma delta T cells and dendritic cells in anti-mycobacterial immune response

2004

D6 is a decoy and scavenger receptor for inflammatory CC chemokines. D6-deficient mice were rapidly killed by intranasal administration of low doses of Mycobacterium tuberculosis. The death of D6(-/-) mice was associated with a dramatic local and systemic inflammatory response with levels of M. tuberculosis colony-forming units similar to control D6-proficient mice. D6-deficient mice showed an increased numbers of mononuclear cells (macrophages, dendritic cells, and CD4 and CD8 T lymphocytes) infiltrating inflamed tissues and lymph nodes, as well as abnormal increased concentrations of CC chemokines (CCL2, CCL3, CCL4, and CCL5) and proinflammatory cytokines (tumor necrosis factor alpha, int…

T cells Dendritic cells
researchProduct

A SUBSET OF VGAMMA9 VDELTA2 T CELLS HELP B CELLS FOR ANTIBODY PRODUCTION.

2006

researchProduct

Additional file 1: of CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA

2015

(a) Characterization of isolated exosomes. Left panel: DSL for exosomes released by SKHep Middle panel: Western blot forTsg101 and HSC70 in SkHep cells and their relative exosomes. Right panel: Confocal microscopy analysis on HUVECs treated for 1, 3 and 6 hours with 5 mg/ml of SKHep-derived exosomes. HUVECs were stained with phalloidin Alexa Fluor (green), nuclear counterstaining was performed using DAPI (blue), exosomes were labelled with PKH26 (red). (b) Target analysis. Real time-PCR analysis on HUVECs treated for 18 h with 5 mg/ml of SkHep-derived exosomes. Normalized for b-actin the DDct were indicated as fold of induction respect to control (untreated cells). *p<0.05. (c) Tubulogen…

embryonic structures
researchProduct

Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During Mycobacterium Tuberculosis Infection and Correlate With Active Disease

2018

T-cell-mediated immune responses play a fundamental role in controlling Mycobacterium tuberculosis (M. tuberculosis) infection, and traditionally, this response is thought to be mediated by Th1-type CD4+ T-cells secreting IFN-γ. While studying the function and specificity of M. tuberculosis-reactive CD4+ T-cells in more detail at the single cell level; however, we found a human CD4+ T-cell population with a naive phenotype that interestingly was capable of producing multiple cytokines (TCNP cells). CD4+ TCNP cells phenotyped as CD95lo CD28int CD49dhi CXCR3hi and showed a broad distribution of T cell receptor Vβ segments. They rapidly secreted multiple cytokines in response to different M. t…

0301 basic medicinelcsh:Immunologic diseases. AllergyAdultCD4-Positive T-LymphocytesMaleTuberculosisTuberculosiReceptors Antigen T-Cell alpha-betaPopulationImmunologyNaive cellMycobacterium tuberculosiBiologyImmunophenotypingMycobacterium tuberculosis03 medical and health sciencesYoung AdultImmune systemAntigenT-Lymphocyte SubsetsCD4 T-cellsmedicineImmunology and AllergyHumanseducationCytokineOriginal Researcheducation.field_of_studyAntigens BacterialLatent tuberculosisT-cell receptorMycobacterium tuberculosismedicine.diseasebiology.organism_classificationPhenotypecytokines3. Good healthCD4 Lymphocyte Count030104 developmental biologyPhenotypenaive cellstuberculosisCD4 T-cellImmunologyDisease ProgressionFemalelcsh:RC581-607Frontiers in Immunology
researchProduct

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

2010

The potent anti-tumour activities of gamma delta T cells have prompted the development of protocols in which gamma delta-agonists are administered to cancer patients. Encouraging results from small Phase I trials have fuelled efforts to characterize more clearly the application of this approach to unmet clinical needs such as metastatic carcinoma. To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a V gamma 9V delta 2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients. Treatment was well tolerated and promoted the effector maturation of V gamma 9V delta 2 T …

Translational Studiesmedicine.medical_treatmentLymphocyte ActivationZoledronic AcidMetastasisTNF-Related Apoptosis-Inducing LigandProstate cancerT-Lymphocyte SubsetsImmunology and AllergyMedicineDiphosphonatesRemission InductionEsterasesImidazolesReceptors Antigen T-Cell gamma-deltaMiddle AgedMetastatic breast cancerTreatment Outcomemedicine.anatomical_structureDisease ProgressionCytokinesFemaleImmunotherapyBreast diseaseChemokinesT cellImmunologyBreast NeoplasmsInterferon-gammaHemiterpenesOrganophosphorus CompoundsBreast cancerAdjuvants ImmunologicVgamma9Vdelta2 T cells Zoledronate interleukin-2advanced breast cancer patientsHumansLymphocyte CountAgedCell ProliferationSalvage Therapybusiness.industryLysineMucin-1CancerImmunotherapymedicine.diseaseTumor Necrosis Factor Receptor Superfamily Member 7ImmunologyInterleukin-2Leukocyte Common Antigensbusiness
researchProduct

CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA

2015

Background CD90+ liver cancer cells have been described as cancer stem-cell-like (CSC), displaying aggressive and metastatic phenotype. Using two different in vitro models, already described as CD90+ liver cancer stem cells, our aim was to study their interaction with endothelial cells mediated by the release of exosomes. Methods Exosomes were isolated and characterized from both liver CD90+ cells and hepatoma cell lines. Endothelial cells were treated with exosomes, as well as transfected with a plasmid containing the full length sequence of the long non-coding RNA (lncRNA) H19. Molecular and functional analyses were done to characterize the endothelial phenotype after treatments. Results …

Cancer ResearchAngiogenesisAngiogenesis; CD90+ liver cancer cells; Exosomes; Long-non-coding RNA H19; Antigens Thy-1; Cell Adhesion; Cell Line Tumor; Endothelial Cells; Exosomes; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; RNA Long Noncoding; Phenotype; Molecular Medicine; Oncology; Cancer ResearchBiologyCD90+ liver cancer cellsExosomesCell LineSettore BIO/13 - Biologia ApplicataCancer stem cellCell Line TumormedicineCell AdhesionHuman Umbilical Vein Endothelial CellsHumansCD90AntigensThy-1TumorExosomes Long-non-coding RNA H19 CD90+ liver cancer cells AngiogenesisResearchLiver NeoplasmsCancerEndothelial Cellsmedicine.diseaseMicrovesiclesCell biologyEndothelial stem cellPhenotypeOncologyembryonic structuresThy-1 AntigensRNAMolecular MedicineRNA Long NoncodingLong NoncodingAngiogenesisStem cellLiver cancerLong-non-coding RNA H19Molecular Cancer
researchProduct

γδ T cells as a potential tool in colon cancer immunotherapy

2014

γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, the combined upregulation of T-cell receptorand NKG2D ligands on tumor cells and induction of NKG2D expression on γδ T cells may greatly enhance tumor killing and unlock the functions of γδ T cells. Here, we briefly review current data on the mechanisms of γδ T-cell recognition and killing of colon cancer cells and propose that γδ T cells may represent a promising target for the…

Cytotoxicity ImmunologicColorectal cancermedicine.medical_treatmentImmunologyNkg2d ligandsLarge rangeLigandsDownregulation and upregulationT-Lymphocyte SubsetsmedicineHumansImmunology and AllergyIn patientCell-mediated cytotoxicitybusiness.industryReceptors Antigen T-Cell gamma-deltaImmunotherapymedicine.diseaseNKG2Dgamma delta cellcolon cancerOncologyColonic NeoplasmsImmunologyNeoplastic Stem CellsImmunotherapybusinessImmunotherapy
researchProduct

Decreased serum granulysin levels in childhood tuberculosis which reverse after therapy

2007

Abstract Granulysin is a cytolytic protein of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Serum levels of granulysin are related to host cellular immunity. We used an ELISA to quantify granulysin serum levels in children with tuberculosis (TB), before and after chemotherapy. The study involved children affected by different clinical forms of TB (n=72) and healthy control children (n=150) from the same geographical area and of similar socio-economic background. Serum granulysin levels before the initiation of TB therapy were significantly lower in children with TB compared to controls, with the lowest levels being found in TB patients who were PPD skin test negative. No sta…

Antigens Differentiation T-LymphocyteMaleMicrobiology (medical)Cellular immunityTuberculosisTuberculosimedicine.medical_treatmentImmunologyAntitubercular AgentsMicrobiologyArticleDisease activityAntigenSerum granulysinmedicineHumansTuberculosisCytotoxic T cellDisease activityGranulysinChildTuberculosis PulmonaryChildhood tuberculosisChemotherapybusiness.industrymedicine.diseaseCoculture TechniquesInfectious DiseasesChild PreschoolTuberculosis MeningealImmunologyFemaleTherapybusinessBiomarkersTuberculosis
researchProduct

Squamous Cell Tumors Recruit γδ T Cells Producing either IL17 or IFNγ Depending on the Tumor Stage

2017

Abstract The identification of reciprocal interactions between tumor-infiltrating immune cells and the microenviroment may help us understand mechanisms of tumor growth inhibition or progression. We have assessed the frequencies of tumor-infiltrating and circulating γδ T cells and regulatory T cells (Treg) from 47 patients with squamous cell carcinoma (SCC), to determine if they correlated with progression or survival. Vδ1 T cells infiltrated SSC tissue to a greater extent than normal skin, but SCC patients and healthy subjects had similar amounts circulating. However, Vδ2 T cells were present at higher frequencies in circulation than in the tissue of either cancer patients or healthy donor…

Male0301 basic medicineCancer ResearchChemokineCell typeSkin Neoplasmsmedicine.medical_treatmentImmunologyCell03 medical and health sciencesInterleukin 21Lymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemT-Lymphocyte SubsetsTumor MicroenvironmentmedicineHumansCytotoxic T cellImmunology; Cancer ResearchAgedNeoplasm StagingAged 80 and overTumor microenvironmentbiologyImmunotherapyMiddle Aged030104 developmental biologymedicine.anatomical_structureImmunologyCarcinoma Squamous Cellbiology.proteinCytokinesFemale030215 immunologyCancer Immunology Research
researchProduct

Plasma granulysin levels and cellular interferon-gamma production correlate with curative host responses in tuberculosis, while plasma interferon-gam…

2007

Contains fulltext : 52707.pdf (Publisher’s version ) (Closed access) Granulysin is a recently identified cytolytic protein which is expressed by human cytotoxic T-lymphocytes and natural killer (NK)-cells, and has broad antimicrobial and tumoricidal activity. Circulating granulysin levels are associated with T- and NK-cell activity, and may thus reflect protection-associated cellular immune responses. In a case-control study in Indonesia, a highly tuberculosis (TB)-endemic country, we therefore determined plasma granulysin levels in adults with active pulmonary TB before, during, and after TB treatment, both in mild/moderate-TB and advanced-TB patients, and compared these to healthy neighbo…

AdultAntigens Differentiation T-LymphocyteMaleMicrobiology (medical)TuberculosisAdolescentInfectious diseases and international health [NCEBP 13]TuberculosiImmunologyEnzyme-Linked Immunosorbent AssayBiologySeverity of Illness IndexMicrobiologyInterferon-gammaImmune systemAntigenImmunitymedicineHumansCytotoxic T cellInterferon gammaPlasma granulysinCellular granulysinCellular IFN-gGranulysinDisease severityTuberculosis PulmonaryAgedImmunity CellularInterferon-gamma productionPoverty-related infectious diseases [N4i 3]Immunotherapy gene therapy and transplantation [UMCN 1.4]Middle Agedmedicine.diseasePathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCase-Control StudiesPlasma IFN-gImmunologyFemaleMicrobial pathogenesis and host defense [UMCN 4.1]medicine.drugImmunity infection and tissue repair [NCMLS 1]
researchProduct

Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy

2008

Summary We report that a recently developed combined immunotherapy (CIT) has the capacity to prevent a spontaneous relapse of replicating Mycobacterium tuberculosis bacilli in the lungs of BALB/c, C57Bl/6 or C3H/HeJ strains of mice, following 4 weeks of non-sterilising treatment with isoniazid and rifampicin. The CIT regimen, represented by recombinant IFNγ, anti-α crystalline monoclonal IgA antibody and IL-4 neutralizing polyclonal antibody, reduced the 8-week relapse of viable bacterial counts in the lungs most significantly, when CIT was inoculated during the 5th week post infection, i.e. during the 3rd week of chemotherapy. Although CIT enhanced lung granuloma area, nitric oxide, cytoki…

MaleMicrobiology (medical)TuberculosisTuberculosiAntibodiemedicine.medical_treatmentImmunologyAntitubercular AgentsColony Count MicrobialMicrobiologyAntibodiesMycobacterium tuberculosisInterferon-gammaMiceAdjuvants ImmunologicRecurrencemedicineAnimalsalpha-CrystallinsRelapseTuberculosis PulmonaryCytokineMice Inbred BALB CMice Inbred C3HChemotherapyLungbiologybusiness.industryTuberculosis; Cytokines; Antibodies; Immunotherapy; RelapseIsoniazidMycobacterium tuberculosisImmunotherapybiology.organism_classificationmedicine.diseaseCombined Modality TherapyRecombinant ProteinsImmunoglobulin AMice Inbred C57BLRegimenInfectious Diseasesmedicine.anatomical_structureModels AnimalImmunologyInterleukin-4ImmunotherapybusinessRifampicinmedicine.drugTuberculosis
researchProduct

IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice.

2007

The influence of Th2 cytokines in tuberculosis has been a matter of dispute. Here we report that IL-4 has a profound regulatory effect on the infection of BALB/c mice with Mycobacterium tuberculosis. Depletion of IL-4 with a neutralizing mAb caused only evanescent reduction of lung infection, but when combined with i.n. inoculations of IgA anti-mycobacterial alpha-crystallin mAb and mouse rIFN-gamma, we observed a 40-fold reduction of the bacterial counts in the lungs at 3 wks following i.n. infection (p<0.001). In genetically deficient IL-4-/- BALB/c mice, infection in both lung and spleen was substantially reduced for up to 8 wks without further treatment. Reconstitution of IL-4-/- mice w…

Tuberculosismedicine.medical_treatmentImmunologySpleenNitric OxideBALB/cMicrobiologyProinflammatory cytokineMycobacterium tuberculosisInterferon-gammaMiceImmunitymedicineImmunology and AllergyAnimalsTuberculosis PulmonaryMice KnockoutMice Inbred BALB CbiologyMacrophagesImmunization PassiveImmunotherapyMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseAntibodies Bacterial infections Cytokines TuberculosisImmunity InnateImmunoglobulin Amedicine.anatomical_structureImmunologybiology.proteinInterleukin-4AntibodyEuropean journal of immunology
researchProduct

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

2007

Abstract The increasing evidence that γδ T cells have potent antitumor activity suggests their value in immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this end, we initiated a phase I clinical trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the γδ T-cell agonist zoledronate, either alone or in combination with low-dose interleukin 2 (IL-2), to activate peripheral blood γδ cells. Nine patients were enlisted to each arm. Neither treatment showed appreciable toxicity. Most patients were treated with zoledronate + IL-2, but conversely only two treated with zoledronate displayed a significant long-te…

Interleukin 2MaleCancer ResearchNeoplasms Hormone-Dependentmedicine.medical_treatmentT cellT-LymphocytesAntineoplastic AgentsLymphocyte ActivationZoledronic AcidArticleMetastatic carcinomaProstate cancerAntigenMedicineHumansAgedAged 80 and overSalvage TherapyBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryRemission InductionImidazolesProstatic NeoplasmsReceptors Antigen T-Cell gamma-deltaImmunotherapyMiddle Agedmedicine.diseaseVγ9Vδ2 T cellsZoledronateIL-2Hormone-refractory prostate cancerImmunotherapyCytokinemedicine.anatomical_structureTreatment OutcomeOncologyImmunologyFeasibility StudiesInterleukin-2Tumor necrosis factor alphaDrug Therapy CombinationImmunotherapybusinessmedicine.drug
researchProduct

Anti-16-kilodalton mycobacterial protein immunoglobulin M levels in healthy but purified protein derivative-reactive children decrease after chemopro…

2007

ABSTRACT Serum responses against Mycobacterium tuberculosis HSP16 were determined for children with tuberculosis (TB) and for healthy purified protein derivative (PPD)-positive and PPD-negative children. Immunoglobulin G (IgG) and IgM responses were higher for TB patients than for other groups. After chemotherapy, IgM and IgG responses decreased for TB patients and PPD-positive subjects. Monitoring of anti- M. tuberculosis HSP16 responses could assist in the management of pediatric TB.

Microbiology (medical)TuberculosisAdolescentChaperoninsmedicine.medical_treatmentClinical BiochemistryImmunologyAntitubercular AgentsTuberculinEnzyme-Linked Immunosorbent AssayTuberculinChemopreventionImmunoglobulin GMicrobiologyKilodaltonMycobacterium tuberculosisBacterial ProteinsmedicineHumansTuberculosisImmunology and AllergyChildChemotherapyMycobacterium tuberculosis IgMpurified protein derivative chemoprophylaxisbiologybusiness.industryClinical and Diagnostic Laboratory ImmunologyMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseImmunoglobulin MImmunoglobulin MChild PreschoolImmunoglobulin GImmunologyChemoprophylaxisbiology.proteinbusiness
researchProduct

Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocyte…

2008

A small series of aminobisphosphonates (N-BPs) structurally related to zoledronic acid was synthesized with the aim of improving activity toward activation of human gammadelta T cells and in turn their in vivo antitumor activity. The absence of the 1-OH moiety, together with the position and the different basicity of the nitrogen, appears crucial for antitumor activity. In comparison to zoledronic acid, compound 6a shows a greater ability to activate gammadelta T cells expression (100 times more) and a proapoptotic effect that is better than zoledronic acid. The potent activation of gammadelta T cells, in addition to evidence of the in vivo antitumor activity of 6a, suggests it may be a new…

T cellAntineoplastic AgentsApoptosisMice SCIDLymphocyte ActivationMiceStructure-Activity RelationshipAntigenIn vivoCell Line TumorDrug DiscoverymedicineAnimalsHumansStructure–activity relationshipAminesCytotoxicityDiphosphonatesMolecular StructureChemistryReceptors Antigen T-Cell gamma-deltaBiological activityIn vitromedicine.anatomical_structureBiochemistryMechanism of actionDrug DesignCancer researchMolecular Medicinemedicine.symptomaminobisphosphonates gammadelta-T lymphocytes
researchProduct

Memory and effector CD8 T cell subsets in human tuberculosis.

2006

researchProduct

Prevalenza di Osteoporosi e Osteopenia in una popolazione adulto-anziana: Zabut Aging Project

2004

researchProduct

A novel ELISA system for detecting serum granulysin in tuberculosis patients

2006

researchProduct

Sintesi e attività antitumorale di derivati dell'acido ursolico

2014

Settore CHIM/06 - Chimica Organicaacido ursolico attività antitumorale HCT116
researchProduct

Memory and effector CD8 T cell subset in human tuberculosis.

2006

researchProduct

Effetto del polimorfismo genico del gene CYP1B1 sul metabolismo estrogenino e sulla densità ossea

2004

researchProduct